Dr Jotte speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about treating stage IV squamous NSCLC with anti-PD-L1 atezolizumab and chemotherapy.

In this study, 29% of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone.

He also describes a doubling of progression-free survival (PFS) benefit with this combination, noting that this came with an increased rate of severe side effects.

For more on these results, watch his interview with ecancer, and read our news coverage here.

Slides from this presentation are available here.